SOURCE: Xtalks

Xtalks Webinars

June 14, 2016 07:00 ET

Learn About Laboratory Considerations When Developing Multiple Myeloma Trials, New Webinar Hosted by Xtalks

The Webinar Taking Place on Thursday, June 30, 2016 at 11am EDT (4pm BST/UK) Will Focus on Important Laboratory Considerations When Designing Clinical Trials in Multiple Myeloma

TORONTO, ON--(Marketwired - June 14, 2016) - Multiple myeloma accounts for approximately 15% of all hematopoietic malignancies and has a bleak prognosis. In response, the pharmaceutical industry is engaged in considerable efforts to develop new treatments using well-designed clinical trials to determine safety and efficacy. Clinical trials in multiple myeloma often utilize a number of laboratory investigations to support primary efficacy endpoints and, therefore, the correct deployment, performance and evaluation of these laboratory investigations is crucial to the successful development of new treatments.

Join keynote speakers Marc Golightly, Professor of Pathology at Stony Brook University and consultant at ICON Laboratory Services, and Dr. Domenica Gandini, Medical Director at ICON Clinical Research, for an informative session including a Q&A with the audience.

Learn more or register for this complimentary event at: Learn About Laboratory Considerations When Developing Multiple Myeloma Trials

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit
For information about hosting a webinar visit

Image Available:

Contact Information